Hot melt extrusion beats batch in cost

In drug-making operations, use of hot melt extrusion, a continuous processing technology, tops batch processing by requiring less offline testing and fewer operator interventions, which can yield improved product quality. It requires no hazardous solvents or water or drying equipment. The technique is compatible with process analytical technology and scales easily. Though it remains an uncommon way of manufacturing drugs, tech developments are making it a more attractive process option. Article

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.